奥妥珠单抗(Obinutuzumab) - 药物靶点：CD20_在研适应症：狼疮性肾炎，CD20阳性B细胞慢性淋巴细胞白血病，CD20阳性滤泡性淋巴瘤_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Afutuzumab、Anti-CD20 monoclonal antibody R7159、Gazyvaro

+ [22]

靶点

CD20

作用方式

抑制剂

作用机制

CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、ADCC(抗体依赖的细胞毒作用)、CD20定向的溶细胞作用

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [6]

在研适应症

狼疮性肾炎CD20阳性B细胞慢性淋巴细胞白血病CD20阳性滤泡性淋巴瘤+ [48]

非在研适应症

CD20阳性弥漫性大B细胞淋巴瘤CD20阳性血液肿瘤肉芽肿伴多血管炎+ [15]

原研机构

Roche Glycart AG

在研机构

F. Hoffmann-La Roche Ltd.

罗氏（中国）投资有限公司

Celgene Corp.

+ [18]

非在研机构

Janssen-Cilag Ltd.Janssen-Cilag GmbH

Roche Nederland BV

权益机构

Biogen, Inc.

Nippon Shinyaku Co., Ltd.

Genentech, Inc.

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (2013-11-01),

慢性淋巴细胞白血病

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)

登录后查看时间轴

结构/序列

Sequence Code 68713L

来源: *****

Sequence Code 9699891H

来源: *****

关联

342

项与奥妥珠单抗相关的临床试验

NCT07003295

/ Recruiting临床2期IIT

A Phase II Study of Glofitamab for Relapsed/Refractory Mantle Cell Lymphoma in Patients Previously Treated With CD19-Directed CAR T-Cell Therapy

This phase II trial tests the safety and side effects of glofitamab and obinutuzumab and how well they work in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory) after receiving CD19-directed chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy is a form of immunotherapy where the immune system cell, T-cell, is changed to attack cancer cells. Glofitamab is a bispecific antibody that can bind to two different antigens at the same time. Glofitamab binds to CD3, a protein found on T cells (a type of white blood cell), and CD20 a protein found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Giving glofitamab and obinutuzumab may be safe, tolerable, and/or effective in treating patients with relapsed or refractory mantle cell lymphoma after receiving CD19-directed CAR T-cell therapy.

开始日期2026-08-14

申办/合作机构

National Cancer Institute

NCT07502872

/ Not yet recruiting临床2期IIT

TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).

开始日期2026-05-01

申办/合作机构

Brown University

[+3]

NCT07441954

/ Not yet recruiting临床1/2期IIT

A Prospective, Multicenter, Phase I/II Clinical Study of Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma.

To explore the maximum tolerated dose (MTD) of pomalidomide in combination with obinutuzumab in patients with relapsed/refractory indolent lymphomas (including follicular lymphoma, marginal zone lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma) treated with the pomalidomide plus obinutuzumab combination regimen, and to determine the recommended phase II dose (RP2D); concurrently evaluating the efficacy and safety of pomalidomide combined with obinutuzumab in patients with relapsed/refractory indolent lymphomas.

开始日期2026-03-20

申办/合作机构

中国医学科学院血液病医院

100 项与奥妥珠单抗相关的临床结果

登录后查看更多信息

100 项与奥妥珠单抗相关的转化医学

登录后查看更多信息

100 项与奥妥珠单抗相关的专利（医药）

登录后查看更多信息

1,109

项与奥妥珠单抗相关的文献（医药）

2026-05-01·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Systematic review of real-world data on the effectiveness and safety profiles of first-line therapies in chronic lymphocytic leukemia

Review

作者: Stożek-Tutro, Anita ; Małowicka, Monika ; Kawalec, Paweł ; Janiszewska, Klaudia

OBJECTIVE:

To assess the real-world effectiveness of first-line targeted therapies (1LTT) for chronic lymphocytic leukemia (CLL) and compare these outcomes with those reported in randomized controlled trials (RCT).

METHODS:

A systematic review of MEDLINE and EMBASE was conducted to identify real-world data (RWD). Key endpoints included progression-free survival (PFS), overall survival (OS), time-to-next treatment (TTNT), and treatment discontinuation due to adverse events (TdAE). CRD42024549185.

RESULTS:

Ibrutinib (IBR) demonstrated consistent effectiveness in multiple RWD studies, with 12- and 24-month OS rates of 87-100% and 78-100%, respectively, and PFS rates of 76-94% and 68-94%, respectively, aligning with the results of the RESONATE-2 trial. Zanubrutinib (ZAN) showed a 36-month OS rate of 92% and a PFS rate of 84%, consistent with the outcomes of the SEQUOIA trial. For acalabrutinib (ACA), 12- and 24-month OS was 86-94% and 76-88%, PFS 92% and 81%, respectively, in line with the ELEVATE-TN trial, similarly, for venetoclax+obinutuzumab (VEN+OBI), 12-and 24-month OS was 94% and 86-94%, PFS 94% and 88%-92%, consistent with the CLL14 trial results. In contrast, idelalisib+rituximab (IDE+RTX) was associated with lower 24-month OS (77%), PFS (68%), and the highest TdAE rate (63%).

CONCLUSIONS:

Among 1LTT for CLL, IBR has the most extensive and consistent RWD, with results mirroring RCT outcomes. ZAN, ACA and VEN+OBI show promising results based on RWD, however, these data are less extensive but consistent with RCT outcomes. Findings highlight the value of RWD and the need for more robust data on newer agents.

2026-04-01·Kidney International Reports

Glucocorticoid reduction in Glomerular Diseases

Review

作者: Massicotte-Azarniouch, David ; Hesketh, Caitlin ; Fairhead, Todd ; Toal, Michael ; Canney, Mark

Glucocorticoids (GCs) remain central to the management of many glomerular diseases, providing rapid and potent antiinflammatory effects. However, their well-recognized toxicities have driven growing efforts to reduce cumulative exposure. This review synthesizes evidence from randomized and key noncontrolled studies evaluating GC-sparing strategies across diseases where these agents have historically played a central therapeutic role. In antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), large trials such as the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) trial and the Effect of Reduced-Dose versus High-Dose Glucocorticoids Added to Rituximab (LoVAS) trial demonstrate that reduced-dose regimens preserve efficacy while lowering infection risk. In lupus nephritis (LN), lower-dose strategies and early use of multipronged regimens incorporating targeted agents such as belimumab, calcineurin inhibitors, or obinutuzumab support faster tapering. In minimal change disease (MCD), combination approaches with calcineurin inhibitors or mycophenolate achieve remission with less steroid exposure. In IgA nephropathy (IgAN), practice is increasingly shifting away from GC use altogether, as novel immunomodulatory agents targeting disease-specific pathways are integrated into care. Although GCs will likely remain essential for induction in select inflammatory glomerulopathies, their role can increasingly be narrowed to early, time-limited use. Future studies should address key uncertainties, particularly the optimal use of i.v. methylprednisolone in rapidly progressive presentations and evaluate the safety and efficacy of even lower-dose regimens.

2026-03-01·Kidney International Reports

Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous Nephropathy

Article

作者: Trillini, Matias ; Surdi, Livia ; Diadei, Olimpia ; Podestà, Manuel Alfredo ; Peracchi, Tobia ; Cugini, Daniela ; Carrara, Fabiola ; Fidone, Diego ; Portalupi, Valentina ; Rubis, Nadia ; Marasà, Maddalena ; Casiraghi, Federica ; Guarinoni, Chiara ; Villa, Alessandro ; Ruggenenti, Piero ; Martinetti, Davide ; Gennarini, Alessia ; Rizzo, Paola ; Remuzzi, Giuseppe ; Currado, Annachiara ; Todeschini, Marta

Introduction:

Approximately 30% of patients with primary membranous nephropathy (MN) and persistent nephrotic syndrome (NS) fail rituximab therapy through mechanisms that could be overcome by obinutuzumab.

Methods:

In this prospective, single-arm, single-center, open-label trial, 20 consenting adults with MN and rituximab-resistant NS received three 1000 mg obinutuzumab infusions at the Bergamo Nephrology Unit (Italy) between March 2022 and February 2024 and were monitored for ≤ 12 months. The primary outcome was a composite end point of normo-albuminemia and complete (proteinuria < 0.3 g/d) or partial (proteinuria < 3.5 g/d with ≥ 50% reduction from baseline) NS remission at 12-month follow-up. Twenty-four-hour proteinuria and glomerular filtration rate (GFR) were evaluated at baseline and at 3, 6, 9, 12, 18, and 24 months posttreatment.

Results:

At 12 months, 16 patients met the combined end point, 4 with complete remission. No patient relapsed after remission. Median (interquartile range) 24-h proteinuria decreased from 5.7 (4.7-8.1) to 1.3 (0.5-2.7) g/24 h. Albumin and IgG fractional clearances also decreased, whereas serum albumin increased from 2.9 ± 0.6 g/dl to 3.9 ± 0.3 g/dl (P < 0.0001 for all changes). Dyslipidemia, hypocalcemia, and hypo-gammaglobulinemia improved significantly and GFR stabilized. At 12 months, total B cells and circulating anti-phospholipase A₂ receptor (PLA₂R) antibodies were depleted. Similar findings were observed in the cohort of 10 patients who completed 24 months of follow-up. However, total B cells reemerged in the circulation without an increase in anti-PLA₂R antibodies and proteinuria, or relapses. Treatment was safe and well-tolerated.

Conclusion:

Obinutuzumab treatment is extremely effective and safe in patients with MN and rituximab-resistant NS and can achieve persistent remission in this population.

941

项与奥妥珠单抗相关的新闻（医药）

2026-04-02

·氨基观察

和铂医药长效TSLP双抗首例受试者入组；全球首个小分子GLP-1获批

氨基观察-创新药组原创出品作者 | 黄恺和铂医药研发加速度。日前，药物临床试验登记与信息公示平台，和铂医药长效TSLP双抗HBM7575的I期临床研究（CTR20260913）已完成首例受试者入组。全球首个小分子GLP-1获批。 4月1日，礼来宣布，美国FDA已批准Foundayo上市，在配合低热量饮食与增加体育锻炼的前提下，每日1次口服用于治疗成人肥胖症，或伴有体重并发症的超重成人患者。该药物将通过礼来直供平台（LillyDirect®）发售，4月6日起发货，随后将迅速在美国零售药房及远程医疗服务机构全面上架。在过去的一天里，国内外医药市场还有哪些热点值得关注？让氨基君带你一探究竟。 / 01 / 医药动态 1）和铂医药HBM7575首例受试者入组日前，药物临床试验登记与信息公示平台，和铂医药长效TSLP双抗HBM7575的I期临床研究（CTR20260913）已完成首例受试者入组。 2）长春高新注射用GenSci136临床试验申请获受理 4月2日，长春高新公告，控股子公司金赛药业收到国家药监局签发的《受理通知书》，其自主研发的注射用GenSci136境内生产药品注册临床试验申请获得受理，该药品拟用于治疗眼肌型重症肌无力(oMG)。 3）悦康药业YKYY018雾化吸入剂获临床许可 4月2日，悦康药业公告称，公YKYY018雾化吸入剂用于人偏肺病毒治疗与预防的临床，获得许可。 4）罗氏奥妥珠单抗新适应症递交上市申请 4月2日，据CDE官网公示，罗氏奥妥珠单抗注射液的一项新适应症上市申请获得受理，推测本次申报的适应症为用于 2 岁及以上原发性肾病综合征患者的治疗。 / 02 / 海外药闻 1）全球首个小分子GLP-1获批 4月1日，礼来宣布，美国FDA已批准Foundayo上市，在配合低热量饮食与增加体育锻炼的前提下，每日1次口服用于治疗成人肥胖症，或伴有体重并发症的超重成人患者。该药物将通过礼来直供平台（LillyDirect®）发售，4月6日起发货，随后将迅速在美国零售药房及远程医疗服务机构全面上架。 PS：欢迎扫描下方二维码，添加氨基君微信号交流。

上市批准申请上市

2026-04-02

·抗体圈

全球首个狼疮肾炎单抗！奥妥珠单抗国内上市申请获 CDE 受理

近日，国家药品监督管理局药品审评中心（CDE）最新公示显示，罗氏旗下奥妥珠单抗注射液的进口上市注册申请正式获受理，受理号为JXSS2600025，注册分类为2.2类。本次上市申请针对的正是活动性狼疮肾炎（LN），意味着这款全球首个获批该适应症的抗CD20单抗，正式开启了中国上市的审批进程，为国内狼疮肾炎患者带来了全新的治疗希望。一、奥妥珠单抗：CD20单抗的迭代升级，从血液瘤到自免的跨界突破奥妥珠单抗是罗氏研发的第二代糖基化改造的II型抗CD20单克隆抗体，也是全球首个糖基化改造的II型抗CD20单抗。与第一代CD20单抗相比，其通过对Fc段的糖基化改造，大幅增强了抗体依赖性细胞介导的细胞毒性（ADCC）作用，能更高效、更彻底地清除B细胞，同时保留了直接诱导B细胞凋亡的能力，在疗效、安全性上实现了双重优化。该产品最早于2021年在中国获批上市，最初适应症为慢性淋巴细胞白血病（CLL），后续又获批用于滤泡性淋巴瘤（FL）等B细胞非霍奇金淋巴瘤，成为淋巴瘤治疗领域的核心药物之一。而近年来，奥妥珠单抗的临床探索持续向自身免疫性疾病领域延伸，尤其是在系统性红斑狼疮（SLE）及狼疮肾炎领域，取得了里程碑式的突破。二、狼疮肾炎治疗的重大突破：III期研究数据奠定上市基础狼疮肾炎是系统性红斑狼疮最常见、最严重的并发症之一，约40%-60%的SLE患者会出现肾脏受累，若控制不佳，10年内约20%的患者会进展为终末期肾病，需要透析或肾移植，严重影响患者的生存质量和生存期。目前国内狼疮肾炎的标准治疗以糖皮质激素联合吗替麦考酚酯（MMF）等免疫抑制剂为主，但仍有超过50%的患者无法实现完全肾脏缓解，且长期大剂量激素使用会带来感染、骨质疏松、代谢紊乱等严重副作用，临床存在巨大的未满足需求。奥妥珠单抗在狼疮肾炎领域的关键III期REGENCY研究（NCT04221477）结果，发表于《新英格兰医学杂志》，为本次上市申请提供了坚实的临床证据：研究纳入全球271例活动性Ⅲ型或Ⅳ型狼疮肾炎患者，在标准治疗（MMF+糖皮质激素）基础上，分别接受奥妥珠单抗或安慰剂治疗；治疗76周时，奥妥珠单抗组46.4%的患者达到完全肾脏缓解，显著高于安慰剂组的33.1%，相对风险提升40%；同时，奥妥珠单抗组患者的皮质类固醇用量显著减少，蛋白尿水平、抗dsDNA抗体滴度等炎症指标也得到明显改善，安全性与既往研究一致，未出现新的安全性信号，严重感染发生率与安慰剂组相当。基于该研究结果，奥妥珠单抗已于2025年获美国FDA批准用于治疗活动性狼疮肾炎成人患者，成为全球首个获批该适应症的抗CD20单抗，本次国内上市申请正是其全球获批后的本土化推进。三、罗氏自免管线再下一城，国内患者迎新治疗选择本次奥妥珠单抗狼疮肾炎适应症的上市申请获受理，是罗氏在自身免疫性疾病领域的又一重要进展。除奥妥珠单抗外，罗氏在自免领域已布局托珠单抗、利妥昔单抗等多款重磅药物，覆盖类风湿关节炎、系统性红斑狼疮等多个适应症，而奥妥珠单抗的加入，将进一步完善其在狼疮肾炎领域的治疗布局。对于国内患者而言，奥妥珠单抗的上市将为狼疮肾炎治疗提供全新的靶向治疗选择，有望打破现有治疗的瓶颈，帮助更多患者实现肾脏缓解，减少激素依赖，延缓疾病进展。同时，该产品的上市也将推动国内狼疮肾炎治疗从传统免疫抑制向精准靶向治疗的转型，为后续更多自免领域靶向药物的研发提供参考。四、2.2类注册分类解读：进口药新适应症上市的规范路径本次奥妥珠单抗的注册分类为2.2类，对应《药品注册管理办法》中“境外上市的原研药品申请境内上市，增加境外已上市、境内未上市的新适应症”的情形，属于进口原研药的新适应症上市申请，符合CDE对进口生物制品上市注册的规范要求。该分类意味着奥妥珠单抗的狼疮肾炎适应症已在境外获批上市，本次申请基于境外临床数据，结合国内患者的桥接研究数据，申请在中国境内上市，审批流程将遵循进口药上市注册的相关要求，预计将加速该产品在国内的获批进程。 💬 互动时间对于狼疮肾炎患者而言，奥妥珠单抗的上市最大的价值是提升缓解率，还是减少激素依赖？你更看重哪一点？欢迎在评论区留下你的观点，我们一起讨论！识别微信二维码，添加抗体圈小编，符合条件者即可加入抗体微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

临床3期上市批准申请上市

2026-04-02

·丁香园 Insight 数据库

罗氏「奥妥珠单抗」在国内递交首个非肿瘤适应症上市申请

4 月 2 日，CDE 官网公示，罗氏奥妥珠单抗注射液的一项新适应症上市申请获得受理。根据该药的研究进度和注册分类，Insight 数据库推测本次申报的适应症为用于 2 岁及以上原发性肾病综合征患者的治疗。今年 2 月，该适应症已被 CDE 纳入优先审评。截图来源：CDE 官网奥妥珠单抗（Obinutuzumab）是一种靶向 CD20 的人源化单抗。在海外，该药已获批用于治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤、滤泡性淋巴瘤、狼疮肾炎。在国内，奥妥珠单抗于 2021 年 6 月首次获批上市，与化疗联合用于滤泡性淋巴瘤成人患者。2025 年，奥妥珠单抗的全球销售额为 11.9 亿美元。 2 月 16 日，罗氏宣布，奥妥珠单抗针对原发性膜性肾病成人患者开展的 III 期 MAJESTY 临床试验已达到其主要终点。MAJESTY（NCT04629248）是一项 III 期、随机、开放标签、多中心临床研究，旨在评估奥妥珠单抗在原发性膜性肾病患者中的疗效与安全性。该研究共纳入 142 名受试者，并按 1:1 的比例将其随机分组，分别接受奥妥珠单抗治疗或他克莫司治疗。该研究的主要终点为：在第 2 年（即第 104 周）时达到完全缓解的患者比例。 MAJESTY 研究结果显示，奥妥珠单抗治疗组取得了具有统计学意义且具有临床重要性的积极疗效。与他克莫司治疗组相比，奥妥珠单抗治疗组中有显著更高比例的患者在第 2 年（104 周）实现了完全缓解。该药的安全性特征与此前已充分确立的奥妥珠单抗安全性概况保持一致，且未发现任何新的安全性信号。原发性膜性肾病是一种慢性自身免疫性疾病，可导致潜在的不可逆肾损伤及肾功能减退，是成人原发性肾病综合征最常见的病因。在 10 年内，高达 30% 的原发性膜性肾病患者会进展为肾衰竭，从而需要透析或肾移植等侵入性治疗干预；这不仅对患者及其家庭造成重大影响，同时也给医疗卫生系统带来了沉重的经济负担。罗氏新闻稿指出，MAJESTY 是首项针对原发性膜性肾病开展的全球性 III 期临床试验，奥妥珠单抗有望成为首个获批用于治疗原发性膜性肾病的药物。除了原发性膜性肾病之外，奥妥珠单抗的拟开发非肿瘤适应症还包括特发性肾病综合征、膜性肾病、狼疮性肾炎、罕见免疫介导的肾脏疾病和系统性红斑狼疮等。 Insight 数据库整理了 2026 年全球新药申报上市清单，扫描下方二维码 👇，回复关键词新药报上市即可免费获取（每月初更新一次，目前更新至 2 月）。封面来源：企业logo 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：馨药 PR 稿对接：微信 insightxb 投稿：微信 insightxb；邮箱 insight@dxy.cn

临床3期优先审批上市批准申请上市

100 项与奥妥珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09321	奥妥珠单抗	L01XC15	DB08935

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
狼疮性肾炎	美国	Genentech, Inc.	2025-10-17
CD20阳性B细胞慢性淋巴细胞白血病	日本	Chugai Pharmaceutical Co., Ltd.	2022-12-23
CD20阳性滤泡性淋巴瘤	日本	Nippon Shinyaku Co., Ltd.	2018-07-02
CD20阳性滤泡性淋巴瘤	日本	Chugai Pharmaceutical Co., Ltd.	2018-07-02
滤泡性淋巴瘤	澳大利亚	F. Hoffmann-La Roche Ltd.	2014-05-15
慢性淋巴细胞白血病	美国	Genentech, Inc.	2013-11-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
边缘区B细胞淋巴瘤	申请上市	中国	F. Hoffmann-La Roche Ltd.	2019-09-28
膜性肾小球肾炎	临床3期	荷兰	-	2025-10-01
肿瘤溶解综合征	临床3期	美国	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	澳大利亚	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	法国	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	希腊	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	塞尔维亚	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	西班牙	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	中国台湾	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	英国	AbbVie, Inc.	2024-08-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04855695 (AACR2026)	临床1/2期	套细胞淋巴瘤	9	ObinutuzumabAcalabrutinibVenetoclaxnib + ObinutuzumabAcalabrutinibVenetoclax + ObinutuzumabAcalabrutinibVenetoclaxab	願鹽醖網壓糧鏇遞糧鏇(襯獵選鬱選願壓範蓋網) = 築遞廠壓壓範簾觸醖壓廠願鑰願糧糧衊構簾餘 (遞衊廠蓋餘餘積壓淵鹹 )	积极	2026-04-20
				Obinutuzumab (Durable Response)	願鹽醖網壓糧鏇遞糧鏇(襯獵選鬱選願壓範蓋網) = 膚廠壓衊鹽壓築獵醖餘廠願鑰願糧糧衊構簾餘 (遞衊廠蓋餘餘積壓淵鹹 )
NCT04963296 (ALLEGORY, Pubmed \| N Engl J Med \| Company_Website) 人工标引	临床3期	系统性红斑狼疮	303	Obinutuzumab	遞醖衊願網艱築鏇築簾(製網壓願夢壓獵齋鬱鏇) = 繭膚獵壓觸繭廠醖膚鹹餘醖壓鹽糧鑰齋襯製蓋 (製蓋鹽繭築壓鬱簾選簾 ) 更多	积极	2026-03-06
				Placebo	遞醖衊願網艱築鏇築簾(製網壓願夢壓獵齋鬱鏇) = 廠膚糧廠鹽廠衊艱遞願餘醖壓鹽糧鑰齋襯製蓋 (製蓋鹽繭築壓鬱簾選簾 ) 更多
ASH2025	N/A	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤	45	Zanubrutinib+venetoclax	製網觸獵膚衊蓋鹹構積(窪醖鏇衊憲憲製簾網襯) = The most common any grade AE that occurred in 20% or more pts were fatigue (56%), diarrhea (53%), hypertension (31%), nausea (27%), upper respiratory infection (27%), arthralgia (27%), bruising (24%), neutropenia (22%), thrombocytopenia (22%), and rash (20%). No atrial fibrillation was recorded. 襯觸範製襯構鹽鑰齋窪 (構壓鏇鬱遞窪願簾鏇鬱 ) 更多	积极	2025-12-06
ASH2025	N/A	套细胞淋巴瘤	15	ObinutuzumabPomalidomideZanubrutinibVenetoclaxab + ObinutuzumabPomalidomideZanubrutinibVenetoclaxib + ObinutuzumabPomalidomideZanubrutinibVenetoclaxde + ObinutuzumabPomalidomideZanubrutinibVenetoclax	艱鹽夢顧壓獵鬱選淵夢(壓網獵淵鬱選獵範積艱) = neutropenia (in 9 [60.0%] of 15 patients), thrombocytopenia(in 3 [20.0%] of 15 patients), infections (in 2 [13.3%] patients) 壓觸糧範壓餘願鹹醖鬱 (窪願淵糧構製衊構餘淵 )	积极	2025-12-06
ASH2025	N/A	慢性淋巴细胞白血病一线	3,844	Second-generation BTKi	膚網構憲鏇鏇範繭顧糧(蓋鹹繭積鹹願鬱網齋網) = 遞襯範衊蓋餘願顧糧構鬱觸蓋膚衊網構糧膚蓋 (繭夢構積蓋餘顧鬱選艱 )	积极	2025-12-06
				V+O	膚網構憲鏇鏇範繭顧糧(蓋鹹繭積鹹願鬱網齋網) = 獵築壓網願襯製顧膚鑰鬱觸蓋膚衊網構糧膚蓋 (繭夢構積蓋餘顧鬱選艱 )
ASH2025	临床2期	滤泡性淋巴瘤一线	40	Obinutuzumab+Ibrutinib+Venetoclax	餘膚遞襯夢構鏇製範鏇(繭鏇築膚遞糧觸壓鏇願) = 鹹壓壓鹽餘築鹽膚艱繭獵願窪齋鏇鹽鹹網獵顧 (築廠觸醖淵夢醖積襯顧 ) 更多	积极	2025-12-06
NCT04608318 (CLL17, ASH2025)	临床3期	慢性淋巴细胞白血病一线	909	Venetoclax plus Obinutuzumab	鬱膚鬱鬱衊鏇醖築餘艱(選鹽艱鬱顧遞憲廠鏇艱) = 餘艱選觸夢衊選襯製構廠製壓艱憲鹽醖鬱壓淵 (築蓋襯積窪遞鑰範觸顧 ) 更多	积极	2025-12-06
				Venetoclax plus Ibrutinib	鬱膚鬱鬱衊鏇醖築餘艱(選鹽艱鬱顧遞憲廠鏇艱) = 窪簾衊憲窪遞壓鑰壓選廠製壓艱憲鹽醖鬱壓淵 (築蓋襯積窪遞鑰範觸顧 ) 更多
ICLL-07 (ASH2025)	临床2期	慢性淋巴细胞白血病一线	135	Ibrutinib 420 mg/day	簾憲鬱鹽鑰獵簾廠選蓋(鏇獵獵醖願餘繭衊艱鏇) = Twelve patients died, including 2 from cardiac toxicity during treatment with O+I attributable to I (M6 and M7). The ten other deaths are distributed among 4 infections (3 bacterial pneumonias at M38, M55, M50 and 1 COVID 19 at M49), 1 histiocytic sarcoma (M47), 1 myelodysplasia (MDS; M56) and 1 acute myeloid leukemia (AML; M68). Three deaths were due to progression (n=1, M103) or transformation in Richter large B-cel lymphoma (n=1; M54) or Hodgkin lymphoma (n=1; M23). 鑰遞淵繭憲膚獵鬱淵築 (鏇鏇壓網膚壓襯憲襯鹹 ) 更多	积极	2025-12-06
NCT03332017 (ROSEWOOD, ASH2025)	临床2期	滤泡性淋巴瘤	214	zanubrutinib + obinutuzumab	顧鬱艱願簾選廠窪鑰簾(襯遞鏇廠膚願艱鹽鏇選) = 積簾憲鑰蓋鏇顧鹽齋鹹膚鹽顧憲艱繭憲膚鑰糧 (範醖鹹鹹製壓簾艱膚遞 ) 更多	积极	2025-12-06
				obinutuzumab	顧鬱艱願簾選廠窪鑰簾(襯遞鏇廠膚願艱鹽鏇選) = 鬱壓壓壓範襯積鏇顧願膚鹽顧憲艱繭憲膚鑰糧 (範醖鹹鹹製壓簾艱膚遞 ) 更多
CICERO (ASH2025)	N/A	慢性淋巴细胞白血病	45	Acalabrutinib +/- Obinutuzumab	廠淵鬱構艱鏇夢遞糧積(艱壓膚觸襯夢餘遞糧鏇) = 鑰選鏇網選鹹鏇糧齋窪膚淵襯遞蓋醖憲製積鏇 (餘蓋鬱蓋觸廠鹹鏇淵膚 ) 更多	积极	2025-12-06